{"entity":{"id":"mycn","kind":"target","name":"MYCN (N-myc)","aka":["N-myc","NMYC","bHLHe37"],"tldr":"MYCN is a growth-driving gene that some neuroblastomas copy many times over; that amplification is one of the strongest signs the tumour is aggressive and sets the intensity of treatment.","summary":"MYCN encodes the N-myc transcription factor, a paralogue of MYC expressed in the developing neural crest. Amplification (many extra copies, detected by FISH) occurs in about 20 percent of neuroblastomas and places a child in the high-risk group of the INRG and COG classifications whatever the age or stage; it also defines a rare aggressive spinal ependymoma group and is amplified in some medulloblastomas and retinoblastomas. There is no approved MYCN-directed drug; the readout page carries the amplification rule and the risk groups that use it.","asOf":"2026-09-23","wikipedia":"https://en.wikipedia.org/wiki/N-Myc","links":[{"label":"HGNC HGNC:7559","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7559"},{"label":"UniProt P04198","url":"https://www.uniprot.org/uniprotkb/P04198/entry"}],"tags":["biomarker-parent"],"related":["mycn-amp"],"cancers":["neuroblastoma","neuroblastoma-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mycn-amplification","gene-amplification","fish"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"MYCN","role":["drug-target","oncogene-driver","biomarker"],"evidenceTier":"approved-drug","sources":[],"hgnc":"HGNC:7559","ensembl":"ENSG00000134323","uniprot":"P04198","entrez":"4613","biology":"N-myc dimerises with MAX and drives proliferation, ribosome biogenesis and metabolic programmes while repressing differentiation; amplified tumours depend on it and are being targeted indirectly through Aurora A, BET and CDK7 inhibitors.","whereFound":["Neuroblastoma (amplified in about 20 percent)","Spinal ependymoma, MYCN-amplified","Medulloblastoma group 3","Retinoblastoma"],"targetClass":"transcription","prevalence":[]},"route":"/targets/mycn/","neighbours":{"biomarker":[{"id":"mycn-amp","kind":"biomarker","name":"MYCN amplification","route":"/biomarkers/mycn-amp/"}],"cancer":[{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"term":[{"id":"fish","kind":"term","name":"FISH / ISH (in situ hybridisation)","route":"/terms/fish/"},{"id":"gene-amplification","kind":"term","name":"Gene amplification and copy-number change","route":"/terms/gene-amplification/"},{"id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/"}],"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}